Expert Interview
A second look: Discussing current treatment options for CLL and the potential of Nurix Therapeutics' NX-5948, a BTK degrader
Ticker(s): NRIXInstitution: UCI Irvine
- Hematologist and Oncologist, and Associate Professor — Division of Hematology-Oncology, Department of Medicine, UCI School of Medicine.
- Currently manages 200 patients with CLL annually and is familiar with Nurix Therapeutics' BTK degraders NX-2127 and NX-5948.
- Specializes in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), which has been her research focus for more than a decade as a principal investigator of numerous clinical trials of novel agents that have improved the care of these patients.
Can you elaborate on the clinical implications of the 69.2% objective response rate observed in the heavily pretreated patient population in the NX-5948 trial?
How significant are the rapid and deepening clinical responses in CLL patients treated with NX-5948, especially considering the patients' history of resistance to BTK inhibitors?
Added By: catalin_adminWhat impact does the ability of NX-5948 to achieve responses as early as the first scan (8 weeks) have on the overall treatment landscape for relapsed or refractory CLL?
NX-5948 showed efficacy in a patient cohort with a high prevalence of BTK inhibitor resistance mutations. How does this influence the potential role of NX-5948 in the treatment of CLL?
The Phase 1a/b trial included patients with various poor prognostic features, such as TP53 mutations and CNS involvement. What does the response of these subgroups suggest about the robustness of NX-5948?
Added By: catalin_adminWith Nurix planning to advance NX-5948 into pivotal trials in 2025, what key data from the ongoing study will be critical for the next stage of development?
Added By: catalin_adminHow does the safety profile of NX-5948, which was well tolerated across all doses with common adverse events being manageable, compare to existing treatments for relapsed or refractory CLL?
Added By: catalin_adminBeyond CLL, what potential does NX-5948 have for treating other B-cell malignancies, and what are Nurix's plans for exploring these additional applications?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
